Mural Oncology is a protein engineering platform to reimagine cytokine-based immunotherapies for the treatment of cancer.
Mural Oncology has raised $275.0M in total funding. The most recent round was Corporate Round. The last funding was announced in November 2023.
Mural Oncology's investors include Alkermes.
Mural Oncology is headquartered in Waltham, United States.
Mural Oncology is a protein engineering platform to reimagine cytokine-based immunotherapies for the treatment of cancer.
Mural Oncology is at the Corporate Round stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Mural Oncology — Funding & Investors." VCBacked, November 15, 2023, https://www.vcbacked.co/company/mural-oncology. Accessed September 30, 2026.
VCBacked. (2023). Mural Oncology — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/mural-oncology
{{cite web |title=Mural Oncology — Funding & Investors |url=https://www.vcbacked.co/company/mural-oncology |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated